http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2708168-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_602e84c727e976e9f361ebbb6b5781fd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 |
| filingDate | 2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e116ee91f15ae3ee4b71fb579c0f9cad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b12d721ba38cbdb79dbe883f25ae0193 |
| publicationDate | 2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2708168-A1 |
| titleOfInvention | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| abstract | Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents. |
| priorityDate | 2007-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.